News Presentations Publications

FILTERS

TOPICS

CritiTech PES partner NanOlogy Completes Enrollment of Bladder Cancer Clinical Trial

FT. WORTH, (March 9, 2021) — NanOlogy, LLC, a clinical-stage oncology company, today announced that enrollment has been completed in its … Continued

More >

CritiTech PES partner NanOlogy Presents Results of SOR007 (Topical Submicron Particle Paclitaxel) Phase 1/2 Clinical Trial in the Treatment of Cutaneous Metastases at 2020 SABCS®

FT. WORTH, (December 29, 2020) — NanOlogy, LLC, a clinical-stage oncology company, today announced that results from its Phase 1/2 clinical … Continued

More >

CritiTech PES partner NanOlogy Enrolls First Patient in Phase 2 Clinical Trial of NanoPac® for Intratumoral Treatment of Prostate Cancer

Follows completion of a first-in-human dose-rising study of a single focal injection of NanoPac in patients with local prostate cancer … Continued

More >

CritiTech PES partner NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac® in Lung Cancer

First-in-human clinical trial of intratumoral (IT) injections of NanoPac in non-small cell lung cancer (NSCLC) and small cell lung cancer … Continued

More >

CritiTech PES partner NanOlogy Presents Updated Clinical Data on Targeted Injections of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms on DDW2020 Site

Updated clinical data from both trials available through Digestive Disease Week® (DDW) Online Education Site FT. WORTH, (May 14, 2020) — NanOlogy, … Continued

More >

NanOlogy Fact Sheet (Jan 2020)

In patients with solid carcinomas, NanOlogy™ has demonstrated that local administration of patented submicron particles continuously exposes primary tumors to … Continued

More >

Video Highlights of NanoPac® Injection for Pancreatic Cancer

Highlights of the presentation by Dr. Neil Sharma, President, Parkview Cancer Institute; Director of Advanced Interventional Endoscopy and Endoscopic Oncology … Continued

More >

ACG 2019 Poster: NanoPac-2017-01 Mid-Study Report: Safety, Tolerability and Preliminary Efficacy of Intracyctic Submicron Particle Paclitaxel (SPP) for the Treatment of Pancreatic Mucinous Cysts

Slide 1 Pancreatic mucinous cystic lesions have significant potential for malignant transformation1; delivery of SPP as a direct intratumoral injection … Continued

More >

ACG 2019 Plenary Presentation: A Novel EUS-guided Intratumoral Delivery of Submicron Particle Paclitaxel for the Treatment of Locally Advanced Pancreatic Cancer

A novel EUS-guided Intratumoral Delivery of Submicron Particle Paclitaxel for the Treatment of Locally Advanced Pancreatic Cancer. A Prospective Safety, … Continued

More >

CritiTech PES partner NanOlogy’s Clinical Updates on Local Injection of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas

Interim data from both clinical trials presented at the 2019 American College of Gastroenterology (ACG) Conference in San Antonio November … Continued

More >